AnaptysBio Inc is clinical-stage biotechnology company. It is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company develops product candidates to address emerging biological targets using its proprietary, antibody discovery techno... AnaptysBio Inc is clinical-stage biotechnology company. It is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company develops product candidates to address emerging biological targets using its proprietary, antibody discovery technology platform, which is designed to replicate, in vitro, the natural process of antibody generation. Its product candidates are ANB020, ANB019, and Checkpoint receptor agonist. The entity generates revenue from the collaborative research and development arrangements. Show more
SAN DIEGO, Feb. 03, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced...
Imsidolimab has successfully completed two global Phase 3 studies in Generalized Pustular PsoriasisVanda expects to immediately begin preparing BLA and MAA applications for the US and EUAnaptys to...
Vanda Pharmaceuticals and Anaptys Announce Exclusive Global License Agreement for Vanda to Develop and Commercialize Imsidolimab, an IL-36R Antagonist PR Newswire WASHINGTON and SAN DIEGO, Feb...
Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.9 | -5.16944284894 | 17.41 | 18.34 | 16.51 | 396320 | 17.40347992 | CS |
4 | 1.39 | 9.19312169312 | 15.12 | 18.34 | 13.51 | 643205 | 15.9742104 | CS |
12 | -5.35 | -24.4739249771 | 21.86 | 26.51 | 12.51 | 655018 | 17.43578558 | CS |
26 | -14.58 | -46.8961080733 | 31.09 | 41.3083 | 12.51 | 502201 | 23.3175891 | CS |
52 | -7.36 | -30.8336824466 | 23.87 | 41.3083 | 12.51 | 420268 | 23.99211971 | CS |
156 | -13.6 | -45.167718366 | 30.11 | 41.3083 | 12.51 | 311889 | 23.19406195 | CS |
260 | 1.47 | 9.77393617021 | 15.04 | 41.3083 | 12.06 | 314166 | 22.7650129 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales